最新研究进展 -MedSci.cn 相关研究进展 -MedSci.cn

Pembrolizumab versus placebo as postnephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, doubleblind, placebo-controlled, phase 3 trial (vol 23, pg 1133, 2022)

期刊： LANCET ONCOLOGY, 2023; 24 (1)

REFINE-Lung implements a novel multi-arm randomisedtrial design to address possible immunotherapy overtreatment

期刊： LANCET ONCOLOGY, 2023; 24 (5)

Increasing evidence suggests that some immunotherapy dosing regimens for patients with advanced cancer could result in overtreatment. Given the high c......

Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

期刊： LANCET ONCOLOGY, 2023; 24 (6)

Background Adding CDK4/6 inhibitor dalpiciclib to fulvestrant significantly prolonged progression-free survival in patients with hormone receptor-posi......

Enhancing colon cancer care in restricted-resource settings

期刊： LANCET ONCOLOGY, 2023; 24 (6)

mRNA vaccine for melanoma

期刊： LANCET ONCOLOGY, 2023; 24 (7)

World's first alcohol health labelling policy to be introduced in Ireland

期刊： LANCET ONCOLOGY, 2023; 24 (7)

Growing liver cancer death rates in the UK call for healthier lifestyle choices

期刊： LANCET ONCOLOGY, 2023; 24 (8)